According to a report published by AMI, the global mRNA vaccines market is anticipate to grow at a CAGR of 19.76% during the forecast period. The rapid advancement in medical technology that promotes the development of mRNA vaccines, coupled with the growth of infectious diseases globally is a major reason for the higher growth in revenue in the global mRNA vaccines market.
mRNA vaccines are being developed for numerous diseases such as cancer (tumors, ovarian cancer, renal cancer, etc.,), infectious diseases ( COVID-19, malaria, Zika virus, etc.,), and other rare diseases. Scientists are increasingly working on developing vaccines to prevent the spread of cancer, which is causing a high disease burden globally. It is the leading cause of death worldwide, claiming about 10 million lives in 2020 alone. Moderna, for instance, is applying their mRNA technology for the development of immunotherapy for cancer. Immune cells in the human body are being trained to identify and destroy cancer cells in the same manner as they fight against foreign organisms that enter the body.
Click on the link to get detailed insights: https://www.absolutemarketsinsights.com/reports/Global-mRNA-Vaccines-Market-2021-2029-1050
Few of the companies profiled in the global mRNA Vaccines Market report are listed below:
- Argos Therapeutics
- BioNTech SE
- c?IMMUNE
- CureVac AG
- eTheRNA
- Genentech, Inc
- Immunomic Therapeutics, Inc.
- Moderna, Inc.
- Pfizer Inc.
- Other Market Participants
Companies are Investing Heavily in Clinical Trials of Various mRNA Vaccines
The report consists of numerous drivers and opportunities that are present in the global mRNA vaccines market. Amongst the major drivers, higher investment in clinical trials to bring out mRNA based vaccines is expected to push the availability of mRNA vaccines, especially for cancer related symptoms in the coming years. Before the pandemic struck, mRNA vaccines were being increasingly studied for cancer-related use. 2021 saw a rapid increase in the clinical trials for mRNA vaccine, driven by the success of the mRNA vaccines by Moderna and Pfizer-BioNTech. BioNTech emerged as the highest investor in oncology-related mRNA vaccine trials, with the company being involved in about 18% of the total clinical trials. CureVac, amongst the earliest investors in mRNA oncology vaccines, reported a 47% efficacy during the phase II/III clinical trial of their CureVac mRNA vaccine. The company is raising its investment to enhance the efficacy of its vaccine in the succeeding trials. The market is expected to see a greater number of clinical trials in mRNA vaccine technology.
Asia Pacific Region is Expected to Emerge as the Fastest Growing Market Due to the Rise in Cases of Both Infectious and Non-Infectious Diseases
The Asia Pacific region is expected to show the highest growth during the forecast years in the global mRNA vaccines market. Countries such as India, China, Japan, etc., are increasingly investing in the development of mRNA vaccines, especially for preventing the spread of cancer and infectious diseases. The rampant spread of the coronavirus in 2020 has raised the focus on mRNA vaccines in the Asia Pacific region. Gennova Biopharmaceuticals, which is based in Pune, India, is developing mRNA vaccine for COVID-19, and the product is expected to hit the market by the mid of 2022. The clinical trial is in the 2/3 phase, and more than 4000 volunteers have been identified for checking the efficacy of the vaccine. These factors are expected to drive the growth of the Asia Pacific mRNA vaccines market in the coming years.
Request for a sample copy of this report: https://www.absolutemarketsinsights.com/request_sample.php?id=1050
Key Industry Developments:
Pfizer BioNTech (BNT162b2), which is an mRNA-based COVID-19 vaccine, has received recommendations from the WHO Strategic Advisory Group of Experts on Immunization (SAGE). The vaccine can be used on individual above the age of five.
Our 402+ pages research study will include extensive information on the following pointers:
- Global Market size and forecast values (2015 – 2029), in terms of revenue (US$ Million) by segments/sub-segments; wherein 2015 to 2019 has been considered as historic years, 2020 as the base year, while 2021 to 2029 will be taken as the forecast period.
- Split of the market revenue (US$ Million) into all the relevant segments & sub-segments across all major regions/countries.
- Market determinants and influencing factors for all major markets.
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Challenges
- Business & Technological Trends
- Covid-19 impact analysis
- Macro-Economic and Micro-Economic Indicators
- Porter’s Five Forces Analysis
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of New Entrants
- Threat of Substitutes
- Competitor's Rivalry
- Market Determinants Radar Chart
- Competitive Benchmarking: Global Presence and Growth Strategies
- Mergers and Acquisitions
- Product Launches
- Investments Trends
- R&D Initiatives
- Market share analysis, taking base year as 2020
- Detailed profiles of major market participants operating in the market, encompassing information on the following pointers:
- Company Details
- Company Overview
- Product Offerings
- Key Developments
- Financial Analysis
- SWOT Analysis
- Business Strategies
- Key Findings
Enquiry before buying this report: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=1050
Global mRNA Vaccines Market
By Clinical Trial Phase
- Preclinical
- Phase I
- Phase II
- Phase III
- Commercial
By Type
- Non-replicating mRNA
- In vivo self-replicating mRNA
- In vitro dendritic cell non-replicating mRNA vaccine
By Indication
- Oncology
- Solid Tumors
- Melanoma
- Prostate cancer
- Ovarian cancer
- Glioblastoma
- HPV + Cancer
- Renal Cancer
- Others
- Infectious Diseases
- COVID-19 vaccine
- Rabies
- Lassa, yellow fever
- Respirational syncytial virus
- Rota
- Malaria
- Universal influenza
- Zika virus
- Multiple sclerosis (MS)
- Epstein-Barr virus (EBV)
- HIV vaccine
- Others
- Rare Diseases
By Vaccine Modality
- Therapeutic
- TME Modulation
- Prophylactic
- DC Vaccine
- T Cell regulation
By Route of Administration
- Intravenous/Intradermal
- Intratumoral
- Intramuscular
By Applications
- Adolescents & Pediatric
- Adults
By End-User
- Healthcare Facilities
- Government Vaccination Campaigns
- Research Facilities
- Others
By Region
- North America
-
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
-
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
-
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
-
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
-
- Brazil
- Argentina
- Rest of Latin America
For Instant Purchase of this Report: https://www.absolutemarketsinsights.com/checkout?id=1050
More Trending Reports by Absolute Markets Insights:
- Phytoene Market By Product Type, Distribution Channel, End-Use, Industry - Global Insights, Growth, Size, Comparative Analysis, Trends And Forecast, 2021 – 2029
- Third-Party Chemical Distribution Market By Service Type, Type, Regional Coverage, Industry Verticals, Region - Global Insights, Growth, Size, Comparative Analysis, Trends And Forecast, 2021 – 2029
Contact Us:
Company: Absolute Markets Insights
Email Id: [email protected]
Phone: IN +91-740-024-2424, US +1-510-420-1213
Contact Name: Shreyas Tanna
Website: www.absolutemarketsinsights.com